ATAD3A and prostate carcinoma: The association with ATAD3A and ATAD3B expression may be of interest since ATAD3 over-expression has been linked to the progression of head and neck cancer, lung adenocarcinoma, non‐Hodgkin's lymphoma, uterine cancer, cervical cancer, prostate cancer, glioma, and hepatocellular carcinoma [46, 63, 64].